180P - Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)

Background

HCC is a leading global cause of cancer mortality, particularly in the Asia-Pacific region (APAC). An understanding of RW tx patterns and outcomes in APAC may inform current disease management. Here we report tx patterns and survival outcomes in a RW population of pts from Taiwan and Singapore with intermediate/advanced HCC.

Methods

This secondary data study from the HCC Registry in Asia (NCT03233360) used third-party (IQVIA) de-identified pt-level data collected retrospectively and prospectively from electronic health records from Taiwan and Singapore, including for pts newly diagnosed with HCC from Jan 2013 to Dec 2019. Descriptive statistics were used to summarize tx patterns (sequence, frequency) and pt characteristics by country and BCLC staging B or C; the Kaplan-Meier method was used to estimate median overall survival (mOS).

Results

Pt characteristics by stage and country are in the table. In Singapore in pts with BCLC B (n = 26), TARE/Y90 was the most common 1st tx (50%) followed by resection (19.2%). In BCLC C pts (n = 22) systemic therapies were common (68.2%). In Taiwan, BCLC B pts (n = 51) were often treated with resection (43.1%) or TACE (31.4%); BCLC C pts (n = 46) were most often treated with systemic therapy (41.3%). mOS in BCLC B pts was 21 mo in Singapore and 25 mo in Taiwan. In BCLC C pts mOS was 4 mo in Singapore and 6 mo in Taiwan.

Conclusions

This study showed utilization patterns of available tx options in and characteristics of HCC pts in Singapore and Taiwan despite the limited sample size. HCC RW data from APAC are scarce. This registry’s data collection, still ongoing outside Taiwan and Singapore, provides useful insights into RW practice and outcomes and illustrates urgent need for new tx options for HCC. As new txs emerge such as atezolizumab + bevacizumab for 1st line tx of unresectable or metastatic HCC, future RW studies extending this work will help reveal their RW impact on pts Table: 180P

Pt characteristics, tx frequency and tx sequence in Singapore and Taiwan

BCLC, Barcelona Clinic Liver Cancer; LRT, locoregional therapy; Syst ther, systemic therapy; TACE, transarterial chemoembolization; TARE/Y90, transarterial radioembolization with yttrium-90 ^a % calculated among all pts receiving a subsequent tx

Clinical trial identification

NCT03233360.

Editorial acknowledgement

Medical writing assistance for this abstract was provided by Chris Lum, PhD of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche, Ltd.

Funding

F. Hoffmann-La Roche, Ltd.

Disclosure

S.P. Choo: Honoraria (self), Advisory/Consultancy: eisai; Honoraria (self), Advisory/Consultancy: Bristol Myers Squibb; Speaker Bureau/Expert testimony: DKSH; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Ipsen. S.K. Mhatre: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech, Inc. A. Ferro: Full/Part-time employment: Genentech/Roche. R. Machado, D.H-C. Liu, N. Irahara: Full/Part-time employment: Roche. V.E. Gaillard: Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche. All other authors have declared no conflicts of interest.